FDA
-
-
-
-
-
-
-
Eiger BioPharmaceuticals (EIGR) to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda
-
-
-
-
-
-
-
Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
-
-
-
-
-
-
-
EIGER ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Eiger Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SolarEdge, Eiger, Unisys, and Rent the Runway and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
Eiger BioPharmaceuticals (EIGR) will not submit EUA application of peginterferon lambda for treatment of patients with mild-to-moderate COVID-19
-
-
-
-
-
-
-
Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2022 Financial Results and Business Update on Thursday, August 4
-
-
-
-
-
-
-
Eiger BioPharmaceuticals Announces Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

